Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C

• Published in: Open forum infectious diseases 2022-06, Vol.9 (6), p.ofac181-ofac181
• Main Authors: Nagot, Nicolas, D’Ottavi, Morgana, Quillet, Catherine, Debellefontaine, Anne, Castellani, Joëlle, Langendorfer, Nicolas, Hanslik, Bertrand, Guichard, Sylvain, Baglioni, René, Faucherre, Vincent, Tuaillon, Edouard, Pageaux, Georges-Philippe, Laureillard, Didier, Donnadieu-Rigole, Hélène
• Format: Article
• Language: English
• Subjects: Human health and pathology; Immunology; Infectious diseases; Life Sciences; Major; Vaccinology
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofac181

Abstract Background Elimination of hepatitis C virus (HCV) among people who use drugs (PWUD) remains a challenge even in countries in which HCV care is provided free of cost. We assessed whether an innovative community-based, respondent-driven sampling (RDS) survey, coupled with HCV screening and immediate treatment, could be efficient to detect and cure current PWUD with chronic HCV in a large city of Southern France. Methods At a community site with peers, PWUD (cannabis not included) were enrolled after confirmation by a urine drug test. Participants were then screened for hepatitis B virus, HCV, and human immunodeficiency virus and benefited from onsite HCV treatment evaluation and prescription. Peer support was provided during treatment, and a systematic visit was scheduled 12 weeks after the end of treatment. The cost of the intervention was estimated. Results Five hundred fifty-four participants were enrolled. Most were male (78.8%) with a median age of 39 years (interquartile range, 33–46). Cocaine (73.1%) and heroine (46.8%) were the main drugs consumed. Overall, 32.6% of PWUD (N = 181) were HCV seropositive, 49 (27.1%) of which had detectable HCV ribonucleic acid and were thus eligible for treatment. Ten of these patients had severe fibrosis. Hepatitis C virus treatment was initiated for 37 (75.5%) patients, 30 (81.1%) of whom completed their treatment and 27 (73.0%) achieved sustained viral response at week 12. The total cost was 161 euros € per screened patient and 1816€ per patient needing treatment. Conclusions A community-based RDS survey approach, involving peers, proved efficient and cost-effective to reach and cure PWUD for HCV. This innovative strategy could be key for the final step of HCV elimination. Clinical trial registration. ClinicalTrials.gov, NCT04008927. Community-based, respondent-driven sampling with peer involvement is very efficient for HCV screening among PWUD. Same-day DAA eligibility check and prescription on site increases treatment initiation. This cost-effective strategy may allow us to achieve HCV elimination among PWUD.